In The News
Featured Evidence
- August 7, 2025
Closing Care Gaps in Diabetes Management Through Advanced Data Integration with Continuous Glucose Monitors
Learn MoreThis article addresses significant disparities in diabetes care within the United States, focusing on the underdiagnosis, undertreatment, and worse health outcomes experienced by minority populations, particularly Black and Hispanic individuals. It highlights the underutilization of Continuous Glucose Monitors (CGMs), a technology proven to improve diabetes management, despite clinical and economic benefits. The authors identify barriers...
- September 17, 2024
Large, Real-World Retrospective Study Shows Reduced Health Care Resource Utilization and Improved Glycemic Outcomes with CGM in T2D Regardless of Treatment Type
Learn More
- April 28, 2024
CGM Improves Glycemic Control and Reduces CVD Risk in Non-Insulin-Treated T2D
Learn More
Latest Expert Interview
Advancing Diabetes Quality Improvement Initiatives with Continuous Glucose Monitoring
Expert: Juan Espinoza , MD, Chief Research Informatics Officer, Ann & Robert H. Lurie Children’s Hospital of Chicago NCQA Panel Committee Member, Diabetes Digital Technologies Roundtable participant (NCQA and ADA), NCQA Health Innovation Summit presenter
Summary: Dr. Espinoza discusses evolving quality measures and their potential to advance diabetes management by incorporating a more comprehensive approach. In addition, he provides an overview of the value realized by payers and providers from integration of CGM data directly into the electronic health record.
Watch Now View All Interviews-
June 9, 2025Continuing Education Programs: Improving Diabetes Outcomes with CGM
Download a comprehensive listing of continuing education (CE) programs for pharmacists, physicians and nurses on the topic of CGM.
-
April 21, 2025Study Shows Additive Effect of CGM and Semaglutide in People with T2D
Among semaglutide users with T2D, use of CGM was associated with greater decreases in A1c compared to non-CGM users, regardless of insulin therapy. Reductions in A1c were greater for CGM users (-0.85%) compared to the control group (-0.29%) in the overall cohort (differences-in-differences (DID), -0.55%, P<0.0001). The proportion of CGM and semaglutide users who met…
-
January 16, 2025Study Shows Disparities in CGM Prescribing for Vulnerable Patient Populations
In a recent cross-sectional study of electronic health record data, researchers found low rates of CGM prescription orders among Federally Qualified Health Center patients with type 1 diabetes (T1D) and type 2 diabetes (T2D). A total of 1,168 patients with T1D and 35,216 patients with T2D were included. Overall, CGM prescriptions were infrequent, with 11.0%…
-
January 10, 2024AMCP Market Insights Health Plan Best Practice: Implementing continuous glucose monitoring to improve patient outcomes in diabetes
Leveraging an opportunity for health plans to support improved patient outcomes in diabetes management with CGM, AMCP sponsored a multifaceted initiative to identify best practices. The program approach consisted of expert interviews, a national payer survey, and an expert panel workshop with clinical experts and managed care stakeholders. In addition to a national webcast to…
-
June 1, 2023Experts Speak Out Regarding the Importance of Eliminating Barriers to CGM Access
Despite Medicare making strides toward improving access with expanded coverage criteria in recent years, experts in the field of endocrinology are speaking out on the importance of reaching underserved populations with the “potentially life-changing benefits” of CGM technology. In addition to expanded coverage eligibility, Richard M. Bergenstal, MD, noted that access to CGM must be…
-
October 3, 2022Continuous Glucose Monitoring: An Opportunity for Population-Based Diabetes Management
Source: Population Health Management Programmatic integrated approaches have been used successfully and cost-effectively to manage various chronic conditions. The incorporation of rtCGM in similar integrated approaches to diabetes management presents an opportunity to improve quality outcomes and reduce costs on a population level. This publication details the evidence to suggest it may be time to…
-
September 15, 2022Stepping Forward With Real-Time Continuous Glucose Monitoring in the Primary Care Practice
CME INFORMATION Release Date: 9/15/2022 CE Expired TARGET AUDIENCEThis activity is intended for primary care physicians and internal medicine physicians. LEARNING OBJECTIVESUpon completion of this activity, participants will:
-
July 15, 2022Latest Research in Diabetes Technology: Highlights from ATTD 2022
This infographic recaps real-time continuous glucose monitoring (rtCGM) abstracts from the 15th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2022) – where innovation in diabetes medicines and treatments, cutting-edge technologies, and the latest research is presented. These abstracts are pertinent to managed care and payer decision makers and help characterize the value…
-
May 19, 2022ADA Standards of Medical Care: Recommendations for Continuous Glucose Monitoring
The American Diabetes Association (ADA) Standards of Medical Care represent the latest evidence-based recommendations for guiding clinical practice. According to the most recent edition of these guidelines, Level A evidence from the MOBILE study supports the use of real time continuous glucose monitoring (rtCGM) in patients with insulin-treated type 2 diabetes (T2D) regardless of regimen….
-
March 9, 2022Expanding Medicaid Access to Continuous Glucose Monitors
Source: Center for Health Care Strategies Published: January 2022
Value of CGM
more patients using rtCGM achieve HEDIS-compliant HbA1C<8% compared with BGM 1 1. Karter AJ, et al. JAMA. 2021;325:2273-2284. doi: 10.1001/jama.2021.6530.
of patients report modifying lifestyle choices due to rtCGM feedback 2 2. Ehrhardt N, et al. Clin Diabetes. 2020;38:126-131. doi: 10.2337/cd19-0037.
in PMPM savings in T2 diabetes related costs according to claims analyses of rtCGM users
3, 4
3. Norman GJ, et al. Diabetes Technol Ther.
2022;24:520-524. doi: 10.1089/dia.2021.0525.
4. Isaacson B, et al. J Diabetes Sci Technol.
2022;16:383-389. doi: 10.1177/1932296820955228.
